Galmed reports interim results from the open-label part of the armor study with aramchol showing robust fibrosis improvement across multimodality histological assessment

- treatment with aramchol 300mg bid resulted in a high rate of subjects with fibrosis improvement using nash crn, paired ranked reading and artificial intelligence (ai) quantitative digital analysis. - at week 48, both paired and ai evaluations identified more subjects with fibrosis improvement (65% and 100% respectively) compared to nash crn scoring.
GLMD Ratings Summary
GLMD Quant Ranking